Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novo Nordisk announces investment in Chinese plant

Novo Nordisk announces investment in Chinese plant

7th November 2008

Novo Nordisk has today announced an investment in a new insulin production plant in Tianjin, China.

The near-$400 million (254 million pounds) project is intended for use as the company’s primary production base for the Asia Pacific region, supplying China and export markets.

The factory will be built on an 88,000 sq metres site and is set to create 500 new jobs, with Lars Rebien Sorensen, president and chief executive officer of Novo Nordisk saying that it will become “the world’s most modern insulation formation and filling plant”.

He added: “The new plant will help meet the increasing demand for Novo Nordisk’s insulin products in Asia. With the new plant and our R&D centre in Beijing, we will have an even stronger platform for changing diabetes in China.”

China has the second highest number of diabetes sufferers in any single country, after India, recording 40 million people who have the disease.

Additionally, 64 million of the country’s population have impaired glucose tolerance, or prediabetes.

The building of the plant follows on from another factory the company has in the vicinity.

Novo Nordisk’s first site in Tianjin was built in 1996, before expanding in 2002 and 2005.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.